Adrenomedullin stabilizes the lymphatic endothelial barrier in vitro and in vivo

Peptides

Volumn 29, Issue 12, 2008, Pages 2243-2249

  Dunworth, William P ^a,b   Fritz Six, Kimberly L ^a   Caron, Kathleen M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenomedullin; Endothelial; Lymphatic; Lymphography; Permeability; VEGFA

Indexed keywords

ADRENOMEDULLIN; PROTEIN ZO1; RNA; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN A;

ARTICLE; CELL JUNCTION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPH FLOW; LYMPH VESSEL ENDOTHELIUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY;

ADRENOMEDULLIN; ANIMALS; ANTIGENS, CD; CADHERINS; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, LYMPHATIC; HUMANS; LYMPHATIC VESSELS; MEMBRANE PROTEINS; MICE; PHOSPHOPROTEINS; TIGHT JUNCTIONS;

EID: 55949121007     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2008.09.009     Document Type: Article

References (32)

1. Berk D.A., Swartz M.A., Leu A.J., and Jain R.K. Transport in lymphatic capillaries. II. Microscopic velocity measurement with fluorescence photobleaching. Am J Physiol 270 (1996) H330-H337
2. Brell B., Temmesfeld-Wollbruck B., Altzschner I., Frisch E., Schmeck B., Hocke A.C., et al. Adrenomedullin reduces Staphylococcus aureus alpha-toxin-induced rat ileum microcirculatory damage. Crit Care Med 33 (2005) 819-826
3. Breslin J.W., Yuan S.Y., and Wu M.H. VEGF-C alters barrier function of cultured lymphatic endothelial cells through a VEGFR-3-dependent mechanism. Lymphat Res Biol 5 (2007) 105-113
4. Caron K.M., and Smithies O. Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional Adrenomedullin gene. Proc Natl Acad Sci USA 98 (2001) 615-619
5. Chu D.Q., Choy M., Foster P., Cao T., and Brain S.D. A comparative study of the ability of calcitonin gene-related peptide and adrenomedullin(13-52) to modulate microvascular but not thermal hyperalgesia responses. Br J Pharmacol 130 (2000) 1589-1596
6. Cullen V.C., Mackarel A.J., Hislip S.J., O'Connor C.M., and Keenan A.K. Investigation of vascular endothelial growth factor effects on pulmonary endothelial monolayer permeability and neutrophil transmigration. Gen Pharmacol 35 (2000) 149-157
7. Debrah A.Y., Mand S., Toliat M.R., Marfo-Debrekyei Y., Batsa L., Nurnberg P., et al. Plasma vascular endothelial growth factor-A (VEGF-A) and VEGF-A gene polymorphism are associated with hydrocele development in lymphatic filariasis. Am J Trop Med Hyg 77 (2007) 601-608
8. Doods H. Development of CGRP antagonists for the treatment of migraine. Curr Opin Invest Drugs 2 (2001) 1261-1268
9. Doods H., Hallermayer G., Wu D., Entzeroth M., Rudolf K., Engel W., et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 129 (2000) 420-423
10. Fernandez-Sauze S., Delfino C., Mabrouk K., Dussert C., Chinot O., Martin P.M., et al. Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors. Int J Cancer 108 (2004) 797-804
11. Fritz-Six K.L., Dunworth W.P., Li M., and Caron K.M. Adrenomedullin signaling is necessary for murine lymphatic vascular development. J Clin Invest 118 (2008) 40-50
12. Gibbons C., Dackor R., Dunworth W., Fritz-Six K., and Caron K.M. Receptor activity-modifying proteins: RAMPing up adrenomedullin signaling. Mol Endocrinol 21 (2007) 783-796
13. Hinson J.P., Kapas S., and Smith D.M. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 21 (2000) 138-167
14. Hippenstiel S., Witzenrath M., Schmeck B., Hocke A., Krisp M., Krull M., et al. Adrenomedullin reduces endothelial hyperpermeability. Circ Res 91 (2002) 618-625
15. Ho T.W., Mannix L.K., Fan X., Assaid C., Furtek C., Jones C.J., et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70 (2008) 1304-1312
16. Hocke A.C., Temmesfeld-Wollbrueck B., Schmeck B., Berger K., Frisch E.M., Witzenrath M., et al. Perturbation of endothelial junction proteins by Staphylococcus aureus alpha-toxin: inhibition of endothelial gap formation by adrenomedullin. Histochem Cell Biol 126 (2006) 305-316
17. Holmes J.L., Van Itallie C.M., Rasmussen J.E., and Anderson J.M. Claudin profiling in the mouse during postnatal intestinal development and along the gastrointestinal tract reveals complex expression patterns. Gene Expr Patterns 6 (2006) 581-588
18. Honda M., Nakagawa S., Hayashi K., Kitagawa N., Tsutsumi K., Nagata I., et al. Adrenomedullin improves the blood-brain barrier function through the expression of claudin-5. Cell Mol Neurobiol 26 (2006) 109-118
19. Kajiya K., Hirakawa S., and Detmar M. Vascular endothelial growth factor-A mediates ultraviolet B-induced impairment of lymphatic vessel function. Am J Pathol 169 (2006) 1496-1503
20. Kim W., Moon S.O., Sung M.J., Kim S.H., Lee S., So J.N., et al. Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells. Faseb J 17 (2003) 1937-1939
21. Kis B., Deli M.A., Kobayashi H., Abraham C.S., Yanagita T., Kaiya H., et al. Adrenomedullin regulates blood-brain barrier functions in vitro. Neuroreport 12 (2001) 4139-4142
22. Kis B., Snipes J.A., Deli M.A., Abraham C.S., Yamashita H., Ueta Y., et al. Chronic adrenomedullin treatment improves blood-brain barrier function but has no effects on expression of tight junction proteins. Acta Neurochir Suppl 86 (2003) 565-568
23. Kitamura K., Kangawa K., Kawamoto M., Ichiki Y., Nakamura S., Matsuo H., et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192 (1993) 553-560
24. Klausner J.M., Abu-Abid S., Alexander J.S., Hanshke-Mineau R., Goldman G., Morel N., et al. Thromboxane modulates endothelial permeability. Mediators Inflamm 3 (1994) 149-153
25. Leu A.J., Berk D.A., Yuan F., and Jain R.K. Flow velocity in the superficial lymphatic network of the mouse tail. Am J Physiol 267 (1994) H1507-H1513
26. McLatchie L.M., Fraser N.J., Main M.J., Wise A., Brown J., Thompson N., et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393 (1998) 333-339
27. McQuaid K.E., Smyth E.M., and Keenan A.K. Evidence for modulation of hydrogen peroxide-induced endothelial barrier dysfunction by nitric oxide in vitro. Eur J Pharmacol 307 (1996) 233-241
28. Petrova T.V., Makinen T., Makela T.P., Saarela J., Virtanen I., Ferrell R.E., et al. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. Embo J 21 (2002) 4593-4599
29. Roesli C., Mumprecht V., Neri D., and Detmar M. Identification of the surface-accessible, lineage-specific vascular proteome by two-dimensional peptide mapping. Faseb J 22 (2008) 1933-1944
30. Salvatore C.A., Hershey J.C., Corcoran H.A., Fay J.F., Johnston V.K., Moore E.L., et al. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carbox amide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 324 (2008) 416-421
31. Swartz M.A., Berk D.A., and Jain R.K. Transport in lymphatic capillaries. I. Macroscopic measurements using residence time distribution theory. Am J Physiol 270 (1996) H324-H329
32. Temmesfeld-Wollbruck B., Hocke A.C., Suttorp N., and Hippenstiel S. Adrenomedullin and endothelial barrier function. Thromb Haemost 98 (2007) 944-951